STOCK TITAN

MAIA Biotechnology Inc - MAIA STOCK NEWS

Welcome to our dedicated news page for MAIA Biotechnology (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MAIA Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MAIA Biotechnology's position in the market.

Rhea-AI Summary
MAIA Biotechnology, Inc. announces significant support from board members in recent private placement. Independent directors Cristian Luput and Ramiro Guerrero made notable purchases of common stock. The private funding round closed on March 11th, with strong participation from key board members, showcasing confidence in MAIA's cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.29%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces independent directors' share purchases in a recent private placement, reflecting confidence in the company's progress. Ms. Adelina Louie Ngar Yee bought 170,940 shares, emphasizing MAIA's potential in developing cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces a private placement of 578,643 shares of common stock at $2.295 per share to accredited investors, including warrants. The warrants are exercisable after six months and have a term of five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
Rhea-AI Summary
MAIA Biotechnology, Inc. announced a private placement of common stock and warrants, raising approximately $2.9 million. Independent director Mr. Stan V. Smith, Ph.D. purchased 170,940 shares. The Company's immuno-oncology therapies targeting difficult-to-treat cancers received support from five independent directors, showcasing confidence in the science and clinical pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.76%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology appoints Professor Saadettin Kilickap, M.D., an accomplished researcher, to its Scientific Advisory Board, enhancing its cancer research capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.58%
Tags
management
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announced its participation in the 36th Annual ROTH Conference to present its lead candidate THIO, a telomere-targeting anticancer agent showing promising results in non-small cell lung cancer. The Phase 2 trial is nearing completion with strong response rates and potential FDA accelerated approval in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences
Rhea-AI Summary
MAIA Biotechnology, Inc. announces promising results of THIO and ionizing radiation combination for childhood brain cancer treatment at AACR Annual Meeting. The study shows significant decrease in cell proliferation and potent anticancer effects in treatment-resistant DIPG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces positive efficacy data for the combination of THIO 180mg + cemiplimab in third-line treatment of non-small cell lung cancer (NSCLC), achieving a 38% overall response rate (ORR) which significantly exceeds the standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces progress in THIO-101 Phase 2 trial with survival and response data expected soon. The company explores various cancer indications and next-gen molecules. Shareholder Letter by CEO Vlad Vitoc details immuno-oncology candidates and pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
Rhea-AI Summary
MAIA Biotechnology appoints Dr. Remus Vezan, a renowned immuno-oncology leader, to its Scientific Advisory Board. Dr. Vezan's extensive experience in drug development and regulatory affairs, including FDA approvals for blockbuster products, brings valuable expertise to MAIA's clinical-stage biopharmaceutical endeavors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
management
MAIA Biotechnology Inc

NYSE:MAIA

MAIA Rankings

MAIA Stock Data

44.01M
14.55M
22.05%
4.02%
2.61%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Chicago

About MAIA

maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru